Use and Attitudes of Obstetricians toward 3 High-Risk Interventions in MFMU Network Hospitals

Citation

Bousleiman, Sabine Zoghbi; Rice, Madeline Murguia; Moss, Joan E.; Todd, Allison; Rincon, Monica; Mallett, Gail; Milluzzi, Cynthia J.; Allard, Donna; Dorman, Karen F.; & Ortiz, Felecia, et al. (2015). Use and Attitudes of Obstetricians toward 3 High-Risk Interventions in MFMU Network Hospitals. American Journal of Obstetrics & Gynecology, 213(3), 398.e1-11. PMCID: PMC4556564

Abstract

OBJECTIVE: We sought to evaluate the frequency of, and factors associated with, the use of 3 evidence-based interventions: antenatal corticosteroids for fetal lung maturity, progesterone for prevention of recurrent preterm birth, and magnesium sulfate for fetal neuroprotection.
STUDY DESIGN: A self-administered survey was conducted from January through May 2011 among obstetricians from 21 hospitals that included 30 questions regarding their knowledge, attitudes, and practice of the 3 evidence-based interventions and the 14-item short version of the Team Climate for Innovation survey. Frequency of use of each intervention was ascertained from an obstetrical cohort of women between January 2010 and February 2011.
RESULTS: A total of 329 obstetricians (74% response rate) who managed 16,946 deliveries within the obstetrical cohort participated in the survey. More than 90% of obstetricians reported that they incorporated each intervention into routine practice. Actual frequency of administration in women eligible for the treatments was 93% for corticosteroids, 39% for progesterone, and 71% for magnesium sulfate. Provider satisfaction with quality of treatment evidence was 97% for corticosteroids, 82% for progesterone, and 57% for magnesium sulfate. Obstetricians perceived that barriers to treatment were most frequent for progesterone (76%), 30% for magnesium sulfate, and 17% for corticosteroids. Progesterone use was more frequent among patients whose provider reported the quality of the evidence was above average to excellent compared with poor to average (42% vs 25%, respectively; P < .001), and they were satisfied with their knowledge of the intervention (41% vs 28%; P = .02), and was less common among patients whose provider reported barriers to hospital or pharmacy drug delivery (31% vs 42%; P = .01). Corticosteroid administration was more common among patients who delivered at hospitals with 24 hours a day-7 days a week maternal-fetal medicine specialist coverage (93% vs 84%; P = .046).
CONCLUSION: Obstetricians in Maternal-Fetal Medicine Units Network hospitals frequently use these evidence-based interventions; however, progesterone use was found to be related to their assessment of evidence quality. Neither progesterone nor the other interventions were associated with overall climate of innovation within a hospital as measured by the Team Climate for Innovation. National Institutes of Health Consensus Conference Statements may also have an impact on use; there is such a statement for antenatal corticosteroids but not for progesterone for preterm prevention or magnesium sulfate for fetal neuroprotection.

URL

http://dx.doi.org/10.1016/j.ajog.2015.05.005

Reference Type

Journal Article

Year Published

2015

Journal Title

American Journal of Obstetrics & Gynecology

Author(s)

Bousleiman, Sabine Zoghbi
Rice, Madeline Murguia
Moss, Joan E.
Todd, Allison
Rincon, Monica
Mallett, Gail
Milluzzi, Cynthia J.
Allard, Donna
Dorman, Karen F.
Ortiz, Felecia
Johnson, Francee
Reed, Peggy
Tolivaisa, Susan, for the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) Maternal-Fetal Medicine Units (MFMU) Network [
John M. Thorp, Jr., Member
]

PMCID

PMC4556564